15 Jan 2021

Ampio completes 55% patient enrolment in Covid-19 trial

Biopharmaceutical firm Ampio Pharmaceuticals has announced the enrolment of 55% of the participants in its ongoing US Phase I clinical trial of inhalation treatment Ampion (AP-014) for patients with respiratory…

13 Jan 2021

Terns concludes patient enrolment in NASH treatment trial

Clinical-stage biopharmaceutical firm Terns Pharmaceuticals has completed patient enrolment in Phase IIa LIFT study of TERN-101 for treating non-alcoholic steatohepatitis (NASH) patients. A liver-distributed non-bile acid farnesoid X receptor (FXR)…